Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: A randomized, double-blind, placebo-controlled trial

Arthritis and Rheumatism

Volumn 43, Issue 2, 2000, Pages 370-377

  Hawkey, Christopher ^a   Laine, Loren ^b   Simon, Thomas ^c   Beaulieu, Andre ^d   Maldonado Cocco, Jose ^e   Acevedo, Eduardo ^f   Shahane, Aditi ^c   Quan, Hui ^c   Bolognese, James ^c   Mortensen, Eric ^c  

^a QUEEN S MEDICAL CENTRE   (United Kingdom)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d LAVAL UNIVERSITY   (Canada)

^e Inst Munic Rehabilitacion P   (Argentina)

^f Perú   (Peru)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; IBUPROFEN; PLACEBO; ROFECOXIB;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIGESTIVE SYSTEM ULCER; DISEASE SEVERITY; DOSE RESPONSE; ENDOSCOPY; EPIGASTRIC PAIN; FEMALE; GASTRODUODENAL ULCER; HEARTBURN; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; OSTEOARTHRITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT INDICATION;

CYCLOOXYGENASE INHIBITORS; DOUBLE-BLIND METHOD; DUODENAL ULCER; DUODENUM; ENZYME INHIBITORS; GASTRIC MUCOSA; HUMANS; IBUPROFEN; INCIDENCE; INTESTINAL MUCOSA; LACTONES; PLACEBOS; SULFONES;

EID: 0034121667     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(200002)43:2<370::AID-ANR17>3.0.CO;2-D     Document Type: Article

References (27)

1. Fries JF. NSAID gastropathy: the second most deadly rheumatic disease? Epidemiology and risk appraisal. J Rheumatol 1991;18 Suppl 28:6-10.
2. Fries JF, Miller SR, Spitz PW, Williams CA, Hubert HB, Bloch DA. Toward an epidemiology of gastropathy associated with nonsteroidal antiinflammatory drug use. Gastroenterology 1989; 96:647-55.
3. Roth SH. Nonsteroidal anti-inflammatory drug gastropathy: we started it - can we stop it? Arch Intern Med 1986;146:1075-6.
4. Paulus HE. FDA Arthritis Advisory Committee meeting: postmarketing surveillance of nonsteroidal antiinflammatory drugs. Arthritis Rheum 1985;28:1168-9.
5. Silverstein FE, Graham DY, Senior JR, Davies HW, Struthers BJ, Bittman RM, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. Ann Intern Med 1995;123: 241-9.
6. Singh G, Ramey DR. NSAID induced gastrointestinal complications: the ARAMIS perspective - 1997. J Rheumatol 1998;25 Suppl 51:8-16.
7. Laine L. Nonsteroidal anti-inflammatory drug gastropathy. Gastrointest Endosc Clin N Am 1996;6:489-504.
8. Silverstein FE. Improving the gastrointestinal safety of NSAIDs: the development of misoprostol - from hypothesis to clinical practice. Dig Dis Sci 1998;43:447-58.
9. Geis GS, Stead H, Wallemark C-B, Nicholson PA. Prevalence of mucosal lesions in the stomach and duodenum due to chronic use of NSAID in patients with rheumatoid arthritis or osteoarthritis, and interim report on prevention by misoprostol of diclofenac associated lesions. J Rheumatol 1991;18 Suppl 28:11-4.
10. Cryer B. Nonsteroidal anti-inflammatory drugs and gastrointestinal disease. In: Feldman M, Scharschmidt BF, Sleisenger MH, editors. Sleisenger and Fordtran's gastrointestinal and liver disease. 6th ed. Philadelphia: Saunders; 1998, p. 343-57.
11. Meade EA, Smith WL, De Witt DL. Differential inhibition of prostaglandin endoperoxidc synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1993;268:6610-4.
12. Fosslien E. Adverse effects of nonsteroidal anti-inflammatory drugs on the gastrointestinal system. Ann Clin Lab Sci 1998;28: 67-81.
13. Mitchell JA, Akarasereenont P, Thiemermann C, Flower RJ, Vane JR. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci U S A 1994;90:11693-7.
14. Brideau C, Kargman S, Liu S, Dallob AL, Ehrich EW, Rodger IW, et al. A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors. Inflamm Res 1996;45:68-74.
15. Brooks P, Emery P, Evans J, Fenner H, Hawkey CJ, Patrono C, et al. Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and eyclooxygenase-2. Br J Rheumatol 1999;38:779-88.
16. Ehrich E, Schnitzer T, Kivitz A, Weaver A, Wolfe F, Morrison B, et al, for the MK-966 Osteoarthritis Phase II Study Group. MK-966, a highly selective COX-2 inhibitor, was effective in the treatment of osteoarthritis of the knee and hip in a 6-week placebo controlled study [abstract]. Arthritis Rheum 1997;40 Suppl 9:S85.
17. Saag K, Fisher C, McKay J, Ehrich E, Zhao P-L, Bolognese J, et al, for the MK-966 Phase III Protocol 033 Study Group. MK-0966, a specific COX-2 inhibitor, has clinical efficacy comparable to ibuprofen in the treatment of knee and hip osteoarthritis in a 6-week controlled clinical trial [abstract]. Arthritis Rheum 1998;41 Suppl 9:S196.
18. Day R, Morrison B, Luza A, Casteneda O, Strusberg A, Nahïr M, et al, for the Rofecoxib/Ibuprofen Comparator Study Group. A randomized trial of the efficacy and safety of the COX-2 specific inhibitor, rofecoxib, and ibuprofen in patients with osteoarthritis. Submitted for publication.
19. Laine L, Simon TJ, Quan H, Bolognese JA, Hoover ME, Wilson FR, et al. Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than ibuprofen. Gastroenterology 1999;117:776-83.
20. Roth SH, Tindall EA, Jain AK, McMahon FA, April PA, Bockow PI, et al. A controlled study comparing the effects of nabumetone, ibuprofen, and ibuprofen plus misoprostol on the upper gastrointestinal tract mucosa. Arch Intern Med 1993;153:2565-71.
21. Graham DY, White RH, Moreland LW, Schubert TT, Katz R, Jaszewski R, et al. Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Ann Intern Med 1993;119:257-62.
22. Normand S-LT. Meta-analysis: formulating, evaluating, combining, and reporting. Stat Med 1999;18:321-59.
23. Cryer B, Gottesdiener K, Gertz B, Hsieh P, Dalloh A, Feldman M. Effects of a novel cyclooxygenase (COX)-2 inhibitor on gastric mucosal prostaglandin (PG) synthesis in healthy humans [abstract]. Am J Gastroenterol 1996;91:1907.
24. Rack MF, Simon T, Quan H, Bolognese J, Lanza F, Hoover M, et al. Selective inhibition of cyclooxygenase-2 (COX-2) with MK-0966 (250 mg Q.D.) is associated with less gastroduodenal damage than aspirin (ASA) 650 mg Q.I.D. or ibuprofen (IBU) 800 mg T.I.D. Aliment Pharmacol Thcr 1999;13:761-67.
25. Hunt R, Bowen B, James C, Sridhar S, Simon T, Mortensen E, et al. COX-2 specific inhibition with MK-0966 25 or 50 mg Q.D. over 4 weeks does not increase fecal blood loss: a controlled study with placebo and ibuprofen 800 mg T.I.D. [abstract]. Am J Gastroenterol 1998;93:1671.
26. Bjarnason I, Sigthorsson G, Crane R, Simon T, Hoover M, Bolognese J, et al. COX-2 specific inhibition with MK-0966 25 or 50 mg Q.D. does not increase intestinal permeability: a controlled study with placebo (PBO) and indomethacin 50 mg T.I.D. (INDO) [abstract]. Am J Gastroenterol 1998;93:1670.
27. Henry D, Lim LL-Y, Rodriguez LAG, Gutthann SP, Carson JL, Griffin M, et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ 1996;312:1563-6.